Cutaneous T-Cell Lymphoma (CTCL)

About Cutaneous T-Cell Lymphoma (CTCL)

The two most common types of CTCL are mycosis fungoides and Sézary syndrome. Mycosis fungoides primarily affects the skin and may resemble common skin diseases like eczema or psoriasis in the early stages before the appearance of skin tumours.[1] In advanced cases, however, it can spread to the lymph nodes and internal organs.[2] In Sézary syndrome, affected cells are found in both the skin and blood from the outset. Internal organs may also be affected.[1]

Because CTCL can look like common skin diseases, it may take 5–6 years or longer before it is diagnosed.[3] To correctly diagnose CTCL, healthcare professionals may take skin samples to look at under a microscope. Once CTCL is diagnosed, healthcare professionals consider the disease stage and symptoms to determine an effective treatment approach. Treatment may also depend on whether other existing medical conditions are present, such as heart disease or diabetes. If you have CTCL, make sure to ask your healthcare professional if you have questions about CTCL or your treatment.

 

ECP Immunomodulation has been used in the treatment of CTCL for more than 30 years and has demonstrated positive effects, with some people experiencing noticeable or complete clearing of the skin.[1,4,5]

1

 

 1. Mishra A, Porcu P. Blood. 2011; 118: 5717–5718.

AFTER PHOTOPHERESIS
BEFORE PHOTOPHERESIS
CTCL

CTCL stands for cutaneous T-cell lymphoma, which is a rare cancer that affects certain white blood cells called T-lymphocytes, or T-cells. CTCL causes visible skin symptoms as mild as a small rash or as severe as tumours or extensive redness, peeling, burning, soreness, and itchiness all over the body.[1,2] CTCL falls into different categories based on the severity of the disease and symptoms.[6]

ECP stands for Extracorporeal Photopheresis, a treatment that works with a patient’s own immune cells to modulate immune function.[7-9]

 

INDIVIDUAL RESPONSES MAY VARY

In clinical trials, approximately one-third of patients had a response (25% reduction in skin score) within 6 months.


Please see Full Prescribing Information

CTCL The Long Journey.png

References:

1. Knobler R, et al. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1-37.

2. Sokołowska-Wojdyło M, et al. Postepy Dermatol Alergol. 2015;32(5):368-383.

3. Mishra A, Porcu P. Blood. 2011; 118: 5717–5718.

4. Knobler R, et al. Photodermatol Photoimmunol Photomed. 2012;28(5):250-257.

5. Scarisbrick JJ, et al. Br J Dermatol. 2008;158(4):659-678.

6. Trautinger F, et al. Eur J Cancer. 2006;42(8):1014-1030.

7. Marshall SR. Nat Clin Pract Oncol. 2006 Jun;3(6):302-314.

8. Bruserud Ø, et al. Cancer Immunol Immunother. 2014;63(8):757-777.

9. Hart JW, et al. Ther Adv Hematol. 2013;4:320-334.

 

 

Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.

 

© 2018 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.